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Hepatitis C virus (HCV), a positive single-stranded RNA virus, is a major cause of liver disease in humans. Herein we report a 
novel strategy to inhibit the reproduction and translation of HCV using a short RNA, named an Additional RNA, to activate 
the endonuclease activity of Argonaute 2 (Ago2). In the presence of the Additional RNA, the HCV genome RNA has the req-
uisite 12 nucleotides of base-pairing with microRNA-122. This activates the endonuclease activity of Ago2, resulting in 
cleavage and release of the HCV genome RNA from Ago2 and microRNA-122. The free HCV genome RNA would be sus-
ceptible to intracellular degradation, effectively inhibiting its reproduction and translation. This study presents a new method to 
inhibit HCV that may hold great potential for HCV treatment in the future. 
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Hepatitis C is an infectious disease that affects over 3% of 
the worldwide population, especially in developing coun-
tries. There is no vaccine against the Hepatitis C virus 
(HCV), and the currently used drugs such as PEGylated 
interferon , ribavirin, telaprevir, and boceprevir produce 
significant adverse effects [1–4]. Therefore, an alternative 
and specific therapy for HCV is desperately needed. 
HCV is a positive single-stranded RNA virus [5,6]. For 
replication and translation, the HCV RNA genome needs to 
recruit the Argonaute 2 (Ago2) protein, one of the compo-
nents of the RNA-induced silencing complex that mediates 
RNA silencing [7–11]. Ago2 has four domains: N, PAZ, 
MID, and PIWI. The PIWI domain has endonucleolytic 
activity and the PAZ domain binds single-stranded RNA 
[12,13]. Ago2 binds to microRNA (miRNA)-122 (miR-122), 
which is an abundant and liver-specific miRNA that regu-
lates the expression of numerous hepatic genes [14–17]. 
Meanwhile, miR-122 binds to the 5′ untranslated region 
(UTR) of the HCV genome that has two conserved seed-     
sequence sites (S1 and S2) at nucleotides 2–8 [5,14,18]. 
Therefore, Ago2 and miR-122 protect the viral genome 
from the host mRNA decay machinery [14]. Previous stud-
ies have suggested that miR-122 normally functions to reg-
ulate HCV’s association with Ago2 [18]. Depletion of Ago2 
may lead to a reduction in HCV RNA of more than 50%, 
and reduce the ability of miR-122 to stimulate viral transla-
tion [7,14,18]. We hypothesized that releasing the HCV 
genome RNA from Ago2 and miR-122 might be an effec-
tive way to inhibit HCV reproduction and translation, po-
tentially being an efficient way to treat hepatitis C. 
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We previously established a method to assay the activity 
of Ago2 [19]. Here, we have taken advantage of this pro-
tein’s endonucleolytic activity to separate the HCV genome 
RNA from Ago2 and miR-122.  
1  Materials and methods 
1.1  Materials 
Recombinant mammalian Ago2 of purity higher than 97% 
was purchased from Sino Biological Inc. (Beijing, China). 
Nuclease inhibitor RNasin, S1 nuclease, and diethylpyro-
carbonate (DEPC) were purchased from Promega (Madison, 
WI, USA). Tris(2-carboxyethyl)phosphine hydrochloride, 
6-mercapto-1-hexanol, hydrogen peroxide solution (30% 
H2O2), sulfuric acid were ordered from Sigma-Aldrich (St. 
Louis, MO, USA). All other reagents were of analytical 
reagent grade and used as received. P5000 silicon carbide 
paper and alumina powder were purchased from Gaoss Un-
ion (Wuhan, China). 
Oligonucleotides were synthesized and purified by 
TaKaRa Biotechnology Co., Ltd. (Dalian, China). The se-
quences of the oligonucleotides used were as follows: 
miR-122: 5′-UGGAGUGUGACAAUGGUGUUUGU-3′ [6, 
18,20,21]; HCV 5′ UTR: 5′-ACACUCCACCAUGA-SH-3′; 
simulated cleaved HCV 5′ UTR: 5′-ACUCCACCAUGA-SH- 
3′; Additional RNA: 5′-CCAUUGUC-3′; methylene blue 
(MB)-labeled DNA: 5′-TCATGGTGGAGTGT-MB-3′. 
The buffer solutions used were as follows. Stock solution 
for oligonucleotides: 0.1 mmol L1 phosphate-buffered saline 
(PBS) (pH 7.4) containing 1‰ DEPC; RNA immobilization 
solution: 10 mmol L1 Tris-HCl containing 10 mmol L1 
Tris(2-carboxyethyl)phosphine hydrochloride, 0.1 mol L1 
EDTA, and 1‰ DEPC (pH 7.4); Ago2 binding buffer: 20 
mmol L1 Tris-HCl containing 1 unit μL1 RNasin, 50 mmol 
L1 KCl, 1.5 mmol L1 MgCl2, and 1‰ DEPC (pH 7.4); 
hybridization buffer: 1×saline sodium citrate [22]; detection 
buffer: 20 mmol L1 PBS (pH 7.0). All solutions were pre-
pared with double-distilled water that was purified with a 
Milli-Q purification system (Barnstead, Iowa, USA) to a 
specific resistance of >18 M cm. 
1.2  Cleavage of HCV 5′ UTR by Ago2 
Ago2 protein was diluted to 25 nmol L1 with Ago2 binding 
buffer and preincubated with 1 μmol L1 miR-122 at 37°C 
for 30 min, forming the Ago2-miRNA complex [19]. Then, 
HCV 5′ UTR and the indicated concentration of Additional 
RNA were added, and hybridized with miR-122 after incu-
bating at 37°C for 1 h. The complex comprising the HCV 5′ 
UTR, Additional RNA, and miR-122 activates the endonu-
clease activity of Ago2, resulting in cleavage of the HCV 5′ 
UTR.  
1.3  Preparation of HCV 5′ UTR-modified electrode 
The HCV 5′ UTR was modified with thiol so it could be 
immobilized onto a gold electrode surface via gold-sulfur 
chemistry. Before immobilization, the electrode (3 mm in 
diameter) was soaked in piranha solution (70% concentrated 
sulfuric acid, 30% H2O2) for 15 min. Then, it was polished 
carefully with P5000 silicon carbide paper and a microcloth 
with 1.0-, 0.3-, then 0.05-μm alumina powder. After that, 
the electrode was sonicated in ethanol then double-distilled 
water for 5 min each. Finally, the electrode was soaked in 
50% hydrogen nitrate for 30 min, followed by electrochem-
ical activation in 0.5 mol L1 H2SO4 to remove any remain-
ing impurities. After being dried with nitrogen, the electrode 
was incubated with the HCV 5′ UTR for 12 h at 4°C to form 
a self-assembled monolayer of the HCV 5′ UTR on the 
electrode surface. Following a 1-h treatment with 1 mmol 
L1 6-mercapto-1-hexanol, the electrode was rinsed with 
double-distilled water containing 1‰ DEPC. It was then 
ready for further experiments. 
1.4  Assay of Ago2 endonuclease activity activated by 
Additional RNA 
MB-labeled DNA was employed as an electrochemical 
probe. After modification of the electrode with the HCV 5′ 
UTR, it was immersed in 1 mol L1 MB-labeled DNA for 
2.5 h at room temperature for hybridization. Then, 0.2 unit 
L1 of S1 nuclease was added to hydrolyze unpaired DNA 
strands. The cleavage was allowed to proceed for 1 h at 
25°C. Then, the electrode was rinsed with double-distilled 
water containing 1‰ DEPC. It was then ready to be used 
for the following electrochemical measurements. 
1.5  Electrochemical measurements 
Cyclic voltammetry (CV) and differential pulse voltammetry 
(DPV) were performed on a model 430A electrochemical 
analyzer (CH Instruments, Shanghai, China) at room tem-
perature with a three-electrode system consisting of the 
modified gold electrode as the working electrode, a plati-
num auxiliary electrode, and a saturated calomel as the ref-
erence electrode. CV and DPV were carried out in PBS with 
a scan range from 0.05 to 0.45 V. 
2  Results 
2.1  Activation of Ago2 endonuclease activity with Ad-
ditional RNA 
The detailed mechanism of our strategy is as follows. The 
endonuclease activity of Ago2 requires nucleotides 9–12 of 
base-pairing between an miRNA and its target mRNA; 
Ago2 then cleaves the mRNA between the 10th and 11th 
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based-paired nucleotides [23]. However, the seed sequence 
in the viral 5′ UTR of HCV, which binds to miR-122, is less 
than 12 nucleotides long, meaning that Ago2 has no endo-
nuclease activity for HCV. We proposed to introduce a 
short piece of RNA, named an ‘Additional RNA’, to acti-
vate the endonuclease activity of Ago2. Specifically, when 
the Additional RNA binds to miR-122, it can form 12 nu-
cleotides of base-pairing with the HCV 5′ UTR, thus acti-
vating the endonuclease activity of Ago2. When Ago2 
cleaves the HCV 5′ UTR, the latter is released from Ago2 
and miR-122; thus, the protection of the viral genome is 
removed and the RNA will be degraded, effectively inhibit-
ing reproduction and translation of HCV. Therefore, as il-
lustrated in Figure 1, first, Ago2 is preincubated with 
miR-122 to allow the miRNA to bind to Ago2, forming 
Ago2-miRNA complexes. Then, the HCV 5′ UTR and the 
Additional RNA are separately added. Both will hybridize 
to miR-122 with a nick between them. This hybridization 
activates the endonuclease activity of Ago2 and results in 
cleavage of the 5′ end of the HCV 5′ UTR. 
2.2  An electrochemical biosensor to detect cleaved 
HCV 5′ UTR 
To assay the cleavage of the HCV 5′ UTR by Ago2, we 
designed an electrochemical biosensor. This biosensor is 
fabricated with S1 nuclease, which hydrolyzes single-      
stranded regions in DNA-RNA hybrids [24]. As illustrated 
in Figure 2, a gold electrode is immobilized with cleaved 
HCV 5′ UTR through the Au-S bond. Then, the electrode is 
immersed in MB-labeled DNA. The MB-labeled DNA is 
complementary to the cleaved HCV 5′ UTR, but is 2 bp 
longer than it, such that when they hybridize, 2 bp remains 
unpaired. When S1 nuclease is added, the unpaired DNA 
will be hydrolyzed, thus releasing the labeled electrochemi-
cal probe, MB. Accordingly, no electrochemical signal can 
be obtained. If the HCV 5′ UTR is not cleaved, there is no 
unpaired MB-labeled DNA, S1 nuclease has no effect, and 
an electrochemical signal can be obtained. 
2.3  Evidence of HCV 5′ UTR cleavage measured by 
CV 
CV is an efficient tool to investigate the behavior of the 
surface of an electrode. We used this technique to measure 
whether the Additional RNA resulted in a different electro-
chemical response of the HCV 5′ UTR-modified electrode. 
When the Additional RNA was present, nearly no peak 
could be observed (Figure 3A). In the absence of Additional 
RNA, there is thus no digestion of unpaired nucleic acids by  
 
 
Figure 1  Schematic of the strategy to inhibit HCV reproduction and translation by activating the endonuclease activity of Ago2 with an Additional RNA. 
 
Figure 2  Schematic illustration of the electrochemical detection of the cleaved HCV 5′ UTR. 
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S1 nuclease and a pair of typical reduction and oxidation 
peaks for MB can be observed (Figure 3B). 
2.4  More evidence of HCV 5′ UTR cleavage obtained 
by DPV 
We also used DPV in our assay, because this technique can 
be more accurate and sensitive than CV at measuring the 
change in an electrode surface. Figure 4 depicts DPV data 
for different concentrations of Additional RNA. The peak 
current decreased with increasing Additional RNA in the 




Figure 3  Cyclic voltammogram obtained at the HCV 5′ UTR-modified 
electrode with (A) and without (B) the addition of 2 mol L1 Additional 
RNA. Scan rate, 100 mV s1. 
 
Figure 4  Differential pulse voltammograms obtained at the HCV 5′ 
UTR-modified gold electrode for different concentrations of Additional 
RNA. Curves a–d correspond to a concentration of 0, 0.5, 1, and 2 mol 
L1 Additional RNA, respectively. The inset shows the relationship be-
tween the peak current and the concentration of Additional RNA. 
2.5  Confirmation with a simulated cleaved HCV 5′ 
UTR 
To confirm that our biosensor is indeed detecting cleaved 
HCV 5′ UTR, we used a simulated cleaved HCV 5′ UTR, 
whose sequence was the same as that of the cleaved HCV 5′ 
UTR produced by Ago2. For comparison, the simulated 
cleaved HCV 5′ UTR and the HCV 5′ UTR were separately 
immobilized on the surface of the working electrode. As 
shown in Figure 5, the peak current obtained at the simu-
lated cleaved HCV 5′ UTR-modified electrode (curve b) 
was much lower than that at the HCV 5′ UTR-modified 
electrode (curve a). Moreover, the peak current for HCV 5′ 
UTR in the presence of 2 mol L1 Additional RNA (curve 
c)––when nearly all molecules were cleaved––was almost 
identical to that observed for the simulated HCV 5′ UTR 
(curve b). This confirms that the Additional RNA does in-
deed activate Ago2 to cleave the HCV 5′ UTR. 
3  Discussion 
There is no vaccine for HCV, and the currently used drugs 
have very limited efficacy and significant adverse effects. In 
this study, we describe an alternative method to inhibit 
HCV that holds great promise for future HCV treatment. By 
adding a short Additional RNA, we promoted Ago2-mediated 
cleavage of the HCV 5′ UTR, which, in vivo, would leave 
the viral genome prone to intracellular degradation. Our 
custom electrochemical biosensor provides a novel and ef-
fective way to detect the cleavage. 
Our idea and experimental results are similar to RNA in-
terference. Therefore, the introduction of an Additional 
RNA to activate Ago2 and promote target mRNA cleavage 




Figure 5  Differential pulse voltammograms obtained with (a and c) the 
HCV 5′ UTR- and (b) the simulated cleaved HCV 5′ UTR-modified gold 
electrode. In (c), 2 mol L1 of Additional RNA was added, such that 
nearly all the molecules were cleaved. 
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